Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

2 ASX tech shares I’d buy in February

After all the pain experienced by ASX tech shares since November 2021, I think it's a great time to look at that sector for opportunities.

After all the pain experienced by ASX tech shares since November 2021, I think it’s a great time to look at that sector for opportunities.

Due to the nature of software, I think tech businesses can achieve impressive margins and grow quickly. Software can be instantly replicated, whereas making a new table and shipping it across the country has lower margins.

I really like these two ASX tech share names for defensive, yet growing, earnings.

VanEck Video Gaming and Esports ETF (ASX: ESPO)

This exchange-traded fund (ETF) is all about the global gaming and e-sports industry. At the moment there is a total of 26 positions in the portfolio.

This is spread across a few different areas of the gaming sector, but the vast majority of it is allocated to game developers, and semiconductor businesses. Names in the portfolio include NvidiaTencentAdvanced Micro DevicesActivision BlizzardNeteaseNintendoElectronic ArtsRoblox and Take-Two Interactive Software.

E-sports is now achieving very large audience numbers. This is unlocking earnings streams for the companies involved such as media rights, merchandise, ticket sales and advertising.

The index that this ETF tracks has delivered an average return per year of 12.5% over the past five years, despite the higher interest rates.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara is an healthcare ASX tech share. It offers advanced software related to breast screening, for both the patient and the healthcare professionals.

This business has a gross profit margin of over 90%, which means that revenue growth turns into gross profit. It’s currently hurtling towards breakeven as it grows.

The ASX tech share is doing very well in the US, with a market share of using one of Volpara’s products on more than 40% of women in the US who have a breast screening.

The latest quarterly update (for the quarter to December 2022) saw cash receipts rise 42% in constant currency terms to NZ$11.2 million. It also achieved its first positive net cashflow quarter.

If it can start winning market share in Europe, I think it’ll do very well, particularly if it can increase the average revenue per user (ARPU) as its service offers a better understanding of patient risk.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content